Putney Promotes Dr. Anthony Lucas to VP of Product Development
Date: May 17, 2011
Company will continue to deepen its pipeline of new products
Portland, Maine—May 17, 2011— Putney, Inc., a rapidly growing pet pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has promoted Dr. Anthony Lucas, BVMS, PhD, to vice president of product development. In his new position, Dr. Lucas is accountable for delivery of Putney’s pipeline, scientific strategy, and project management involving clinical research organization and development partners.
Dr. Lucas credits his success at Putney to the company’s team-oriented and collaborative spirit which encourages employees to pursue new projects and empowers them to make innovative contributions. “I look forward to expanding Putney’s new product opportunities and applying world class scientific methods to produce high quality FDA Center for Veterinary Medicine approval submissions for new products,” says Lucas.
Jean Hoffman, CEO of Putney, says Lucas’s technical and scientific contributions have propelled Putney to the forefront of the companion animal generic pharmaceutical industry. “We’re looking for more people like Dr. Lucas who want to develop their skills and knowledge, expand their career path, and apply their acquired competencies to new challenges,” says Hoffman.
About Putney
Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney’s reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. Putney’s ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more at www.putneyvet.com.